替吉奥联合顺铂一线治疗晚期非小细胞肺癌的疗效观察

目的观察替吉奥联合顺铂一线治疗晚期非小细胞肺癌的有效性和安全性。方法 44例晚期非小细胞肺癌患者一线接受替吉奥(根据体表面积调整剂量:40～60mg,口服bid,d1～14),联合顺铂(25mg/m2静滴qd,d1～3)化疗。结果化疗客观有效率(CR+PR)为22.7%,疾病控制率(CR+PR+SD)为72.7%。1年生存率为53.5%,中位PFS为5.3个月(95%CI,5.091～5.509)。化疗后常见的毒副作用为口腔黏膜炎及神经毒性,而严重的骨髓抑制发生率较低。结论替吉奥联合顺铂治疗晚期非小细胞肺癌的疗效确切,耐受性良好,给药途径方便,为晚期非小细胞肺癌的治疗提供了一种新的选择。

Efficacy and side effects of combination therapy of cisplatin and S-1 for advanced non-small-cell lung cancer

Objective To evaluate the efficacy and toxicity of treatment with cisplatin plus S-1 in patients with advanced non-small-cell lung cancer（NSCLC）.Methods A total of 44 cases accepted first-line chemotherapy with S-1（dose adjustment based on body surface area： 40-60mg,p.o,d1-14） plus cisplatin（25mg/m2,ivdrip,qd,d1-3）.Results The remission rate（CR＋PR） was 22.7%,and the disease control rate（CR＋PR＋SD） was 72.7%.The 1-year survival rate was 53.5% and median PFS was 5.3 months（95%CI,5.091-5.509）.There was more oral mucositis and neuropathy,and less myelosuppression was found in this study.Conclusion This chemotherapy regimen with cisplatin plus S-1 is a promising treatment for advanced NSCLC because of its high response rates,good survival rates,and mild toxicities.